Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Soligenix | Vintage Vibes

5 Healthcare Stocks On Fire This Week

Five healthcare stocks have emerged as standout performers, posting remarkable week-on-week momentum gains according to the latest Benzinga Edge Ranking report.

Benzinga · Aug 21, 2025

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jul 27, 2022

Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Jul 25, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga · Jul 20, 2022

Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study

The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients with Mild-to-Moderate Psoriasis.

Benzinga · Jun 28, 2022

SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Benzinga · May 24, 2022

Soligenix's Return On Capital Employed Overview

Benzinga Pro data, Soligenix (NASDAQ:SNGX) reported Q4 sales of $251.38 thousand. Earnings fell to a loss of $4.70 million, resulting in a 31.12% decrease from last quarter.

Benzinga · Mar 30, 2022

Read news from The Economist, FT, and more,
with one subscription

Recap: Soligenix Q4 Earnings

Soligenix (NASDAQ:SNGX) reported its Q4 earnings results on Tuesday, March 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 29, 2022

Coverage From

Benzinga

People

David Bautz

41 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Rhythm Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.